Testing a new drug combo for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding a targeted drug, fruquintinib, to the chemotherapy trifluridine/tipiracil works better than the chemotherapy alone for stomach or esophageal cancer that has spread. It's for people who have already tried a few treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or esophageal adenocarcinoma that has spread to other parts of your body.
- You have already tried 2 or 3 separate chemotherapy treatments (including drugs like platinum, fluoropyrimidine, irinotecan, or taxane).
- You are able to be up and about with little or no help (WHO performance status 0–1).
- You have not had a heart attack, stroke, or serious heart condition in the last 6 months.
- You have not taken the study drugs (trifluridine/tipiracil, fruquintinib, regorafenib, or similar VEGFR inhibitors) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—fruquintinib, sintilimab, and XELOX chemo—for advanced stomach cancer. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and FOLFOX chemotherapy) as the first treatment for advanced gastric (stomach) cancer. The goal is to see if this combination is safe and effective in shrinking tumors or slowing the cancer's growth.
This trial tests a combination of targeted therapy (fruquintinib), chemotherapy (nab-paclitaxel), and two immunotherapies (iparomlimab and tuvonralimab) for people with advanced stomach or gastroesophageal junction cancer whose first treatment with a PD-1/PD-L1 inhibitor stopped working. The goal is to see if this new combination can shrink tumors and improve outcomes.
This trial tests a combination of three drugs — a chemotherapy called irinotecan liposome, a targeted therapy called fruquintinib, and an immunotherapy called sintilimab — for people with advanced stomach cancer whose disease has worsened after their first treatment. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of two drugs, fruquintinib and TAS102, for people with advanced stomach cancer that has stopped responding to at least one prior chemotherapy. The goal is to see if this new combination can help shrink tumors or slow the cancer's growth.
This study tests a new combination of two drugs (fruquintinib and sintilimab) plus focused radiation for people with advanced stomach or gastroesophageal junction cancer that has progressed after earlier treatments. The goal is to see if this approach can help control the cancer.
Hear when a new Metastatic Oesogastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.